Actividad laboral en una cohorte de pacientes con carcinoma de pulmón

Villaverde, R. Molina; Batlle, Jaime Feliú; Gordo, A.M. Jiménez; Valiente, Belén San José

doi:10.4321/s0465-546x2012000100002

Cited by 1 publication

(1 citation statement)

References 20 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The activity rate and the average salary of the general population were considered (Supplementary Table S15 ). The percentage of patients on sick leave at the time of diagnosis was 96.90% ( 35 ), assuming that 19% of the diagnosed patients would return to work after 4.5 months ( 36 ) and 11.20% of the non-diagnosed patients would return to work after 9 months ( 35 ). Based on this, the percentage of patients with NSCLC who work throughout the time horizon was estimated (Supplementary Table S16 ).…”

Section: Methodsmentioning

confidence: 99%

Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain

Majem

Álvarez²,

Ortega³

et al. 2022

Grhta

View full text Add to dashboard Cite

Introduction: In recent years, target therapies to specific molecular alterations in advanced non–small cell lung cancer (NSCLC) have been identified and have shown superior efficacy compared to non-targeted treatments. Anaplastic lymphoma kinase (ALK) is one of the therapeutic targets; nevertheless, ALK diagnosis is not performed in all NSCLC patients in Spain. The objective of this study is to estimate in monetary terms the benefit for the Spanish society of ALK diagnosis in advanced NSCLC patients. Methods: A cost-benefit analysis of ALK diagnosis vs. non-diagnosis in advanced NSCLC patients was carried out from the Spanish social perspective, with a time horizon of 5 years. Costs, benefits and the cost-benefit ratio weremeasured. The analysis has considered the overall survival in advanced NSCLC patients treated with the ALKtyrosine kinase inhibitor (TKI) alectinib. The natural history of NSCLC was simulated using a Markov model. A 3% discount rate was applied to both costs and benefits. The result was tested using a deterministic sensitivity analysis. Results: The cost of ALK diagnosis vs. non-diagnosis in the base case would be €10.19 million, generating benefits of €11.71 million. The cost-benefit ratio would be €1.15. In the sensitivity analysis, the cost-benefit ratio could range from €0.89 to €2.10. Conclusions: The results justify the universal application of ALK diagnosis in advanced NSCLC, which generates a benefit for Spanish society that outweighs its costs and allows optimal treatment with targeted therapies for these patients.

show abstract

Section: Methodsmentioning

confidence: 99%